Breaking News
Required *
| Today's Wall Street Journal Reports on Cannabis |
Today's Wall Street Journal Reports on Cannabis Science Inc. in Article on Booming Medical Cannabis Industry; Indicates Great Demand for Products From a Patient Oriented CompanyJuly 23, 2009 SAN FRANCISCO, CA -- (MARKET WIRE) -- Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased that today's Wall Street Journal article on the booming medical cannabis industry in California notes the role of Cannabis Science Inc. Commenting on why Cannabis Science was mentioned in the article, Richard Cowan, chief financial officer of Cannabis Science Inc., said, "Although the company is beginning the FDA approval process for its products, we believe that the inclusion of Cannabis Science Inc. in an article about the struggle to get medical cannabis to patients is further evidence that we are a patient oriented company, whose business strategy does not depend on a continuation of marijuana prohibition." Although the company is not involved in the state's gray market, the article notes, "A pot activist named Richard Cowan has opened what he envisions as an investment bank for pot-related businesses, called General Marijuana (General Marijuana.com). Mr. Cowan is also chief financial officer of Cannabis Science Inc., which is trying to market a pot lozenge for nonsmokers." Please click http://online.wsj.com/article/SB124829403893673335.html to read the article in full. Cannabis Science CEO, Dr. Robert J. Melamede, observed, "This article is further demonstration of the huge need for FDA approved medical cannabis products." Earlier this week, Cannabis Science reported that Dr. Melamede had spoken at a hearing in Denver in opposition to an attempt to undermine a voter-approved constitutional amendment that would have made it much more difficult for patients to get affordable medical marijuana. Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements. Cannabis Science Inc.
|